The company's lead product, Immucin, has received orphan drug status from both the FDA and EMA agencies. Vaxil Bio's patented platform, VaxHit, utilizes the signal peptide domain of MUC1, present in 90% of cancers, to develop cancer immunotherapy products. The company has successfully completed a Phase-I/II trial in multiple myeloma patients, with all participants showing robust immune responses. Vaxil Bio is also working on developing a COVID-19 vaccine and a tuberculosis vaccine/treatment, both of which have shown promising preliminary results. Additionally, the company is evaluating other indications and monoclonal antibody candidates for immuno-oncology and infectious disease treatments.